These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35992783)

  • 41. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
    Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
    Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
    Lavole A; Mazieres J; Schneider S; Brosseau S; Kiakouama L; Greillier L; Guihot A; Abbar B; Baron M; Makinson A; Langlais A; Morin F; Spano JP; Cadranel J;
    Lung Cancer; 2021 Aug; 158():146-150. PubMed ID: 34217967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic vaccines in non-small cell lung cancer.
    Socola F; Scherfenberg N; Raez LE
    Immunotargets Ther; 2013; 2():115-24. PubMed ID: 27471692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
    Seto T; Nosaki K; Shimokawa M; Toyozawa R; Sugawara S; Hayashi H; Murakami H; Kato T; Niho S; Saka H; Oki M; Yoshioka H; Okamoto I; Daga H; Azuma K; Tanaka H; Nishino K; Tohnai R; Yamamoto N; Nakagawa K
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
    Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
    Wong DJ; Bauer TM; Gordon MS; Bene-Tchaleu F; Zhu J; Zhang X; Cha E
    Clin Lung Cancer; 2022 May; 23(3):273-281. PubMed ID: 34456145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I study of the
    Kim C; Liu SV; Subramaniam DS; Torres T; Loda M; Esposito G; Giaccone G
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer.
    Rocco D; Della Gravara L; Battiloro C; Gridelli C
    Expert Opin Biol Ther; 2021 Mar; 21(3):303-309. PubMed ID: 33355496
    [No Abstract]   [Full Text] [Related]  

  • 50. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
    García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
    Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial.
    Ramos TC; Vinageras EN; Ferrer MC; Verdecia BG; Rupalé IL; Pérez LM; Marinello GG; Rodríguez RP; Dávila AL
    Cancer Biol Ther; 2006 Feb; 5(2):145-9. PubMed ID: 16357522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial.
    Xu Y; Huang Z; Fang J; Liu A; Lu H; Yu X; Chen K; Xu X; Ma X; Shi W; Kim YH; Hakozaki T; Addeo A; Shen Y; Li S; Fan Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1069-1078. PubMed ID: 35832454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).
    Heudobler D; Schulz C; Fischer JR; Staib P; Wehler T; Südhoff T; Schichtl T; Wilke J; Hahn J; Lüke F; Vogelhuber M; Klobuch S; Pukrop T; Herr W; Held S; Beckers K; Bouche G; Reichle A
    Front Pharmacol; 2021; 12():599598. PubMed ID: 33796020
    [No Abstract]   [Full Text] [Related]  

  • 58. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
    Molinier O; Besse B; Barlesi F; Audigier-Valette C; Friard S; Monnet I; Jeannin G; Mazières J; Cadranel J; Hureaux J; Hilgers W; Quoix E; Coudert B; Moro-Sibilot D; Fauchon E; Westeel V; Brun P; Langlais A; Morin F; Souquet PJ; Girard N
    ESMO Open; 2022 Feb; 7(1):100353. PubMed ID: 34953398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
    Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.